Short summary

Retrospective register study for patients who diagnosed with renal cell carcinoma and registered in DaRenCa database. We will investigate the recurrence rate in this Danish cohort through the last 5 years and identify the predictors, which have influences on the recurrence. 

---

Rationale

Renal cell carcinoma (RCC) is associated with a significantly higher annual mortality-to-incidence ratio than any other common urological malignancy. About 20-30% of all patients have metastatic disease at the time of diagnosis. In addition, about 20% of the patients who undergo nephrectomy with curative intent have been shown to develop metastatic RCC (mRCC) during follow-up. In most cases, recurrence will develop within the first 5 years after primary surgery. Metastatic renal cancer is associated with a poor prognosis, and early treatment of the metastasis may improve the survival rate.

The aim of this study was to report recurrence rate (RR) following surgery for localized or locally advanced disease and to report cancer specific survival (CSS), and overall survival (OS) in a Danish population.

---

Description of the cohort

Data on patients diagnosed with RCC in DaRenCa database from August 2010 to August 2015 will be analyzed. Tumors stage, tumor size, Fuhrman grade, leibovich score, Charlson score, time of metastasis, time to recurrence and status of death all will be collected from DaRenCa database. With missing data, the relative departments, which responsible for treatment of patient will contact to validate and try to get complete data.

The pathological specimen will be re-evaluated in case there are missing for pathological features in the pathological reports. 

Collaborating researchers and departments

Department of Urology, Odense University Hospital

• Consultant Nessn H. Azawi, MB.Ch.B.

Department of Urology, Herlev University Hospital

• Chairman of Danish Renal Cancer Group Bjarne Kromann-Andersen

Department of Pathology, Aalborg University Hospital

• Astrid Petersen

Department of Oncology, Aarhus University Hospital

• Consultant Frede Donskov, MD